A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Inclusion Criteria: - Informed consent obtained before any trial-related activities.
Trial-related activities are any procedures that are carried out as part of the trial,
including activities to determine the suitability for the trial - Male patients aged 18
years or older at the time of signing informed consent, diagnosed with severe haemophilia A
(FVIII activity below 1%), based on medical records or results at screening Exclusion
Criteria: - Known or suspected hypersensitivity to trial product(s) or related products -
Known inherited or acquired bleeding disorder other than haemophilia A - Presence of
inhibitors (neutralising antibodies) to Factor VIII (equal to or above 0.6 Bethesda Units)
at screening measured by the Nijmegen method